ABSTRACT
Maintaining linear growth and weight gain in HIV-infected children is often difficult. Nutritional evaluation and support are recognised as important factors to improve their quality of life. Combination antiretroviral therapy including protease inhibitors (HAART) reduces HIV-viral load and improves survival, quality of life and nutritional status. Our study aimed to determine changes in nutrional status based on body weight, height and nutritional habits, of HIV-infected children receiving HAART. Possible side effects of lipid metabolism were also studied. Twenty five children, 13 treated with HAART (group B) were followed up for 12 months. We did not observe statistically significant differences in nutritional status over that time or between groups A and B. Inadequate energy intake was more common in patients with advanced HIV-disease. Hyperlipidemia was found in 70% of children receiving ritonavir and in approximately 50% of children receiving nelfinavir. We observed an important although not statistically significative modification in the height of those in group B.
Subject(s)
HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Nutritional Status , Adolescent , Anti-HIV Agents/therapeutic use , Body Height/drug effects , Body Weight/drug effects , Child , Child, Preschool , Drug Therapy, Combination , Female , Humans , Infant , Lipid Metabolism , Longitudinal Studies , MaleABSTRACT
We present a case report of leptospirosis with acute renal failure and hepatic dysfunction. Aspecific clinical presentation and serologic tests do not help therapeutic choices. The patient received 18 sessions of hemodialysis and early treatment with intravenous ceftazidime 1 g tid (under the impression of Gram- sepsis). Third generation cephalosporins, ceftriaxone and cefotaxime, are highly active against Leptospira [10] while clinical experience with ceftazidime is lacking.
ABSTRACT
Ciclosporina A es una nueva alternativa terapéutica utilizada en pacientes con dermatitis atópica severa, tanto en niños como en adultos, con excelente respuesta y tolerancia. Presentamos 15 pacientes en un rango de edad de 4 a 14 años, con diagnóstico de dermatitis atópica severa a quien se les administro Neoral (una nueva formulación de ciclosporina, en microemulsión oral), a una dosis de 3 a 3,5 mg/kg/día, por in período de 1 a 3 meses, se obtuvo una buena respuesta terapéutica sin efecto secundarios de importancia. Concluimos que la Ciclosporina A en microemulsión es una buena alternativa terapéutica en los pacientes en edad pediátrica con diagnóstico de dermatitis atópica severa
